I obtained a PhD in neuroscience from Princeton University, with a major in behavioral neuropharmacology. My post-doctoral research at Harvard Medical School and subsequently at Dartmouth Medical School focused on elucidating the neuropharmacological basis and treatment of alcohol use disorder in patients with schizophrenia. One of my projects here at Penn State is to investigate neural mechanisms underlying the cooccurrence of alcohol use disorder and post-traumatic stress disorder (PTSD). The aim is to develop and characterize an animal model of this psychiatric comorbidity by combining fMRI, electrophysiology, behavioral and optogenetic approaches.
Email: duc289@PSU.EDU
Selected Publications:
Distinct Neural-Functional Effects of Treatments with Selective Serotonin Reuptake Inhibitors, Electroconvulsive Therapy, and Transcranial Magnetic Stimulation and Their Relations to Regional Brain Function in Major Depression: A Meta-analysis. Chau DT, Fogelman P, Nordanskog P, Drevets WC, and Hamilton PJ. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, May 2017, 2:318-326.
Desipramine enhances the ability of paliperidone to decrease alcohol drinking. Chau DT, Khokhar JY, Gulick D, Dawson R and Green AI. Journal of Psychiatric Research, 2015, 69: 9-18.
The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat. Chau DT, Khokhar JY, Dawson R, Ahmed J, Xie H, Green AI. Alcohol, 2013, 47: 611-618.
Fluoxetine alleviates behavioral depression while decreasing acetylcholine release in the nucleus accumbens shell. Chau DT, Rada PV, Kim K, Kosloff RA and Hoebel BG. Neuropsychopharmacology, July 2011, 36(8): 1729-37.